BRAF and neoplasm: Our results showed that after the treatment of dabrafenib combined with trametinib, the PFS and OS of BRAF V600 mutation-positive glioma patients were 6.10 months and 22.73 months, respectively, which showed an anti-tumor activity and improvement of disease progression.